Maximizing TLR9 Activation in Cancer Immunotherapy with Dual-Adjuvanted Spherical Nucleic Acids
Source abstract
Abstract
Nucleic-acid-based immune adjuvants have been extensively investigated for the design of cancer vaccines. However, nucleic acids often require the assistance of a carrier system to improve cellular uptake. Yet, such systems are prone to carrier-associated adaptive immunity, leading to difficulties in a multidose treatment regimen. Here, we demonstrate that a spherical nucleic acid (SNA)-based self-adjuvanting system consisting of phosphodiester oligonucleotides and vitamin E can function as a potent anticancer vaccine without a carrier. The two functional modules work synergistically, serving as each other’s delivery vector to enhance toll-like receptor 9 activation. The vaccine rapidly enters cells carrying OVA model antigens, which enables efficient activation of adaptive immunity in vitro and in vivo. In OVA-expressing tumor allograft models, both prophylactic and therapeutic vaccinations significantly retard tumor growth and prolong animal survival. Furthermore, the vaccinations were also able to reduce lung metastasis in a B16F10-OVA model.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Virus-based gene therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Departments of Chemistry and Chemical Biology, Chemical Engineering, and Bioengineering, Northeastern University, Boston, Massachusetts 02115, United States
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States
Department of Bioengineering, Northeastern University, Boston, Massachusetts 02115, United States
Funding
National Cancer Institute · National Institute of General Medical Sciences · Division of Materials Research
References (36)
Show source-provided references
1. 10.1038/nri.2016.7810.1038/nri.2016.78 ↗
2. 10.1146/annurev-immunol-031210-10134010.1146/annurev-immunol-031210-101340 ↗
3. 10.1038/s41577-020-0288-310.1038/s41577-020-0288-3 ↗
4. 10.3389/fchem.2020.0060110.3389/fchem.2020.00601 ↗
5. Shukla N. M. · 201810.1021/acsmedchemlett.8b00566 ↗
6. 10.1002/med.2164910.1002/med.21649 ↗
7. 10.1126/scitranslmed.aaz660610.1126/scitranslmed.aaz6606 ↗
8. 10.1016/j.apsb.2021.12.0210.1016/j.apsb.2021.12.02 ↗
9. 10.1016/j.matt.2020.08.02710.1016/j.matt.2020.08.027 ↗
10. 10.1080/2162402X.2020.177762510.1080/2162402X.2020.1777625 ↗
11. 10.4161/onci.2093110.4161/onci.20931 ↗
12. 10.1073/pnas.190280511610.1073/pnas.1902805116 ↗
13. 10.1021/acsnano.7b0097810.1021/acsnano.7b00978 ↗
14. 10.1038/s41551-019-0351-110.1038/s41551-019-0351-1 ↗
15. 10.1038/s41563-020-0793-610.1038/s41563-020-0793-6 ↗
16. 10.1038/s41565-020-00781-410.1038/s41565-020-00781-4 ↗
17. 10.1021/acsami.9b2107510.1021/acsami.9b21075 ↗
18. 10.1038/s41565-020-00782-310.1038/s41565-020-00782-3 ↗
19. 10.1016/j.jconrel.2020.03.04010.1016/j.jconrel.2020.03.040 ↗
20. 10.1016/j.nano.2013.02.00610.1016/j.nano.2013.02.006 ↗
21. 10.1016/j.vaccine.2010.02.10310.1016/j.vaccine.2010.02.103 ↗
22. 10.1021/jacs.5b0079510.1021/jacs.5b00795 ↗
23. 10.1158/0008-5472.CAN-12-025710.1158/0008-5472.CAN-12-0257 ↗
24. 10.1016/S0264-410X(98)00151-010.1016/S0264-410X(98)00151-0 ↗
25. 10.1021/jacs.6b0755410.1021/jacs.6b07554 ↗
26. 10.3382/ps.074066610.3382/ps.0740666 ↗
27. 10.1586/erv.10.17410.1586/erv.10.174 ↗
28. 10.1038/sj.onc.121091110.1038/sj.onc.1210911 ↗
29. 10.1016/B978-0-12-804019-5.00009-810.1016/B978-0-12-804019-5.00009-8 ↗
30. 10.1002/adma.20160603610.1002/adma.201606036 ↗
31. 10.1002/eji.183021113610.1002/eji.1830211136 ↗
32. 10.1021/bi991393l10.1021/bi991393l ↗
33. 10.1016/j.celrep.2015.04.00910.1016/j.celrep.2015.04.009 ↗
34. 10.1038/nrc.2015.310.1038/nrc.2015.3 ↗
35. 10.1073/pnas.130580411010.1073/pnas.1305804110 ↗
36. 10.3382/ps.070170910.3382/ps.0701709 ↗